申联生物(688098) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was ¥153,028,601.14, a decrease of 1.03% compared to ¥154,617,434.39 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2021 was ¥44,421,029.76, representing a decline of 26.88% from ¥60,751,575.88 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥38,516,256.84, down 22.87% from ¥49,939,586.74 year-on-year[20]. - The net cash flow from operating activities was ¥2,684,655.94, a significant improvement from a negative cash flow of ¥2,860,364.18 in the same period last year[20]. - Basic earnings per share for the first half of 2021 were ¥0.11, down 26.67% from ¥0.15 in the same period last year[21]. - The weighted average return on net assets decreased by 1.52 percentage points to 3.12% from 4.64% in the previous year[21]. - The company achieved a total revenue of 3,380.84 million RMB in the first half of 2021, an increase from 1,696.79 million RMB in the same period last year, representing a growth of approximately 99%[57]. - The company achieved operating revenue of CNY 153.03 million, a year-on-year decrease of 1.03%[86]. - The net profit attributable to shareholders was CNY 44.42 million, down 26.88% year-on-year, primarily due to increased costs from promoting new products and relocating production lines[86]. Research and Development - The R&D investment as a percentage of operating revenue increased to 19.46%, up 8.97 percentage points from 10.49% in the previous year[21]. - The total R&D investment increased by 83.54% year-on-year, reaching CNY 29,778,425.13, with R&D expenses accounting for 19.46% of operating income[53]. - The capitalized R&D investment surged by 810.34% to CNY 14,663,163.75, significantly impacting the overall R&D investment structure[53]. - The company has successfully innovated five key core technologies for inactivated vaccines, enhancing its product competitiveness[41]. - The R&D team consists of 69 members, accounting for 23.23% of the total workforce, with expertise in various fields related to veterinary medicine and biotechnology[69]. - The company has applied for a total of 86 patents, with 6 new veterinary drug registration certificates obtained during the reporting period[51]. - The company has established multiple advanced technology platforms, including inactivated vaccine technology and virus-like particle vaccine technology, to strengthen its R&D capabilities[62]. Market Position and Products - The company specializes in the research, production, and sales of foot-and-mouth disease vaccines, which are critical for preventing outbreaks in livestock[25]. - The market for veterinary biological products in China reached a sales figure of 162.36 billion in 2020, showing a year-on-year increase of 37.17%[33]. - The average gross margin for the veterinary biological products industry was reported at 63.67% in 2020, indicating a healthy profitability level[33]. - The company is one of the designated producers of foot-and-mouth disease vaccines, which are mandatory for livestock immunization in China[26]. - The company is a leader in the domestic synthetic peptide vaccine field, maintaining the first market share in synthetic peptide vaccines for pigs from 2018 to 2020[40]. - The company has launched a new inactivated vaccine for foot-and-mouth disease, which officially commenced production in February 2021[78]. - The company has developed a new bivalent synthetic peptide vaccine for foot-and-mouth disease (FMD) with strong immunogenicity and safety, which has received a new veterinary drug registration certificate[66]. Financial Management and Investments - The company has established a fundraising management system to ensure that raised funds are used legally and specifically for expanding its vaccine production capabilities[145]. - The total amount of raised funds is CNY 40,017.50 million, with CNY 2,603.98 million invested in the current year[161]. - The cumulative amount of raised funds invested to date is CNY 21,635.63 million, which is 83.56% of the committed investment amount[161]. - The company has committed to using up to CNY 300 million of idle raised funds for cash management in safe, liquid bank financial products[163]. - The company has engaged in cash management by investing in structured deposits with various banks, including Shanghai Pudong Development Bank[165]. - The company plans to continue rolling over the idle funds within the approved limits and timeframe[164]. Environmental Compliance - The company has maintained compliance with all environmental discharge standards, with no exceedances reported for key pollutants such as ammonia nitrogen and chemical oxygen demand[115]. - The company has successfully managed its environmental impact, with no reported exceedances for any monitored pollutants during the reporting period[116]. - The company has implemented measures to ensure that all emissions, including nitrogen oxides and sulfur dioxide, are below regulatory limits[116]. - The company has installed online monitoring facilities for various pollutants, ensuring real-time monitoring of emissions[123]. - The company has conducted regular drills for emergency response plans related to environmental incidents[122]. Corporate Governance and Shareholder Relations - The company is committed to improving its governance structure to protect the rights of shareholders, especially minority shareholders[147]. - The company will strictly fulfill all public commitments made during the initial public offering and listing on the Sci-Tech Innovation Board[14]. - The company has established measures to avoid related party transactions that could harm the interests of shareholders[134]. - The company will ensure compliance with relevant laws and regulations regarding related party transactions[134]. - The company has made commitments that are independently enforceable, ensuring the validity of each commitment[134]. Strategic Initiatives - The company has established a technical service system to support customers, enhancing its market competitiveness through quality and service[70]. - The company has expanded its marketing network and sales team to improve service quality and enhance industry competitiveness[72]. - The company is preparing to expand its product line to include vaccines for other diseases and diagnostic reagents for veterinary use[32]. - The company plans to invest 341.52 million CNY in the construction of animal vaccine facilities, expecting an annual sales revenue increase of 320 million CNY and an annual profit increase of 96 million CNY post-production[97].